Multidrug-resistant tuberculosis is an extremely threatening disease for an individual and a country to contract. TB patients in the Central Asia Region are ten times more likely to have MDR-TB than rest of the world (1). Uzbekistan especially should address their alarming rates of MDR-TB infection and the conditions that cause them. An effective TB treatment and surveillance program, such as DOTS, along with MDR-TB specific programs like DOTS-plus offer the most reliable course towards MDR-TB reduction. Yet the characteristics of Uzbekistan and the difficult nature of TB and MDR-TB treatment make MDR-TB reduction a challenging but necessary task.
[...] “Multidrug-resistant Tuberculosis in Central Asia.” Emerging Infectious Disease. CDC. Atlanta: May Nov 2004. < http:>. “DOTS-Plus for Multidrug-Resistant Tuberculosis.” World Health Organization. Washington D.C.: Nov 2004. < http:>. Dubrovskaya, Elena. “International Doctors Battle Drying Sea in Uzbek Epidemic.” Eurasianet. New York: 25 Apr Nov 2004. < http:> . Dye, Christopher, et. al. “Erasing the World's Slow Strain: Strategies to Beat Multidrug-Resistant Tuberculosis.” Science Magazine Mar 2002; Vol 295, p. 2042- Nov 2004. < http:>. “Health in Europe and Central Asia: Transition Retrospective and Business Plan.” The World Bank. [...]
[...] “Drug Resistant Tuberculosis Levels Ten Times Higher in Eastern Europe and Central Asia.” World Health Organization. Geneva: 16 Mar Nov 2004. < http:>. Schoenemann, Thomas. “Drug Resistant Tuberculosis Levels Ten Times Higher in Eastern Europe and Central Asia.” World Health Organization. Geneva: 16 Mar Nov 2004. < http:>. Mukherjee, Joia S., et. al. “Programmes and Principles n Treatment of Multidrug-Resistant Tuberculosis.” The Lancet. Vol Feb 2004, p 474- Nov 2004. < http: pdf>. Schoenemann, Thomas. “Drug Resistant Tuberculosis Levels Ten Times Higher in Eastern Europe and Central Asia.” World Health Organization. [...]
[...] Vol Feb 2004, p 474- Nov 2004. < http: pdf>. WHO Report Released on the Global Status of Multi-Drug Resistant TB Results. Washington, D.C Nov 2004. < http:>. Schoenemann, Thomas. “Drug Resistant Tuberculosis Levels Ten Times Higher in Eastern Europe and Central Asia.” World Health Organization. Geneva: 16 Mar Nov 2004. < http:>. Sterling, Timothy R., et. al. “Impact of DOTS compared with DOTS-plus on Multidrug Resistant Tuberculosis Deaths: Decision Analysis.” British Medical Journal. BMJ Publishing: 2003 Mar 15; 326(7389): Nov 2004. < http:>. Sterling, Timothy R., et. al. [...]
[...] Combating MDR-TB is essential for improving the health status in Uzbekistan, and although Uzbekistan does not offer a solid foundation to build an intervention on, MDR-TB control and treatment must be implemented to assure that the country's health does not continue to decline at such perilous rates. Endnotes: Schoenemann, Thomas. “Drug Resistant Tuberculosis Levels Ten Times Higher in Eastern Europe and Central Asia.” World Health Organization. Geneva: 16 Mar Nov 2004. < http:>. Dye, Christopher, et. al. “Erasing the World's Slow Strain: Strategies to Beat Multidrug-Resistant Tuberculosis.” Science Magazine Mar 2002; Vol 295, p. [...]
[...] Uzbekistan should make efforts to enhance the skills, supplies, and training of healthcare workers for both tuberculosis and multidrug- resistant TB care. The facilities already in place to aid TB control should be utilized and maximized to their potential. Increasing funding, availability of drug stocks, and awareness of needs to outside alliances should be high priorities as well. Since MDR-TB is essentially preventable, Uzbekistan's vision should reflect their desire to reduce MDR- TB infections to as minimal an amount as possible. [...]
APA Style reference
For your bibliographyOnline reading
with our online readerContent validated
by our reading committee
